BLEPHAMIDE S.O.P Drug Patent Profile
✉ Email this page to a colleague
When do Blephamide S.o.p patents expire, and when can generic versions of Blephamide S.o.p launch?
Blephamide S.o.p is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in BLEPHAMIDE S.O.P is prednisolone acetate; sulfacetamide sodium. There are eighty-eight drug master file entries for this compound. Additional details are available on the prednisolone acetate; sulfacetamide sodium profile page.
Summary for BLEPHAMIDE S.O.P
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | BLEPHAMIDE S.O.P at DailyMed |
US Patents and Regulatory Information for BLEPHAMIDE S.O.P
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | BLEPHAMIDE S.O.P. | prednisolone acetate; sulfacetamide sodium | OINTMENT;OPHTHALMIC | 087748-001 | Dec 3, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |